CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Mineola, New York, United States and 125 other locations
cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...
Phase 3
Stony Brook, New York, United States and 23 other locations
in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...
Phase 2
New York, New York, United States and 41 other locations
be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the saf...
Phase 1, Phase 2
New York, New York, United States and 8 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
New York, New York, United States and 213 other locations
carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian...
Phase 2
Hackensack, New Jersey, United States and 1 other location
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
New York, New York, United States and 46 other locations
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-...
Phase 1
New York, New York, United States and 9 other locations
efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...
Phase 2
Ridgewood, New Jersey, United States and 20 other locations
(PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian ....
Phase 1, Phase 2
New York, New York, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal